Regulatory effect of thalidomide on the expression of costimulatory molecules in patients with multiple myeloma.
- Author:
Yun YANG
1
;
Wang-gang ZHANG
;
Ai-li HE
;
Hui-yun YANG
;
Ying WANG
;
Wei TIAN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; B7-1 Antigen; drug effects; metabolism; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Multiple Myeloma; drug therapy; immunology; pathology; Thalidomide; therapeutic use; Up-Regulation; drug effects
- From: Journal of Southern Medical University 2009;29(12):2470-2476
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the expression of B7 co-stimulatory molecules in human multiple myeloma (MM) and the immunoregulatory effects of thalidomide on B7.1 co-stimulator.
METHODSThe immunoregulatory effects of thalidomide on the expression of B7-1 in human MM cell line was examined by detecting the changes in the expression of B7 co-stimulator on the cells using flow cytometry following the drug treatment.
RESULTSThe expression of B7.1 co-stimulator was lowly expressed in human MM cell line and MM patients, with a positivity rate of 0.8 and (2.19-/+2.13) for B7.1 and a rate of 26.4 and (30.28-/+28.11) for B7.2, respectively. Compared with the control group, the thalidomide-treated cells showed significantly increased percentage of CD-80 positive cells in a dose-dependent manner (but not at 0.1 microg/ml) (P<0.01), with the highest percentage reaching (17.7-/+1.53)% at thalidomide concentration of 5 microg/ml.
CONCLUSIONMM cells express low or undetectable levels of B7.1. Thalidomide can up-regulate the expression of B7-1 molecules on myeloma cells, which is probably one of the therapeutic mechanisms of thalidomide.
